At last follow-up, patients who received daplusiran/tomligisiran had a lower HBsAg level than patients on placebo (1.86 vs 2.63 log IU/mL in placebo group), although this difference did not reach statistical significance [ 53 ].
1
—
—
At last follow-up, patients who received daplusiran/tomligisiran had a lower HBsAg level than patients on placebo (1.86 vs 2.63 log IU/mL in placebo group), although this difference did not reach statistical significance [ 53 ].